Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 259

1.

Effects of Gamma Radiation Sterilization on the Structural and Biological Properties of Decellularized Corneal Xenografts.

Mirazul Islam M, Sharifi R, Mamodaly S, Islam R, Nahra D, Abusamra DB, Chuen Hui P, Adibnia Y, Goulamaly M, Paschalis EI, Cruzat A, Kong J, Nilsson PH, Argüeso P, Eirik Mollnes T, Chodosh J, Dohlman CH, Gonzalez-Andrades M.

Acta Biomater. 2019 Jul 5. pii: S1742-7061(19)30482-9. doi: 10.1016/j.actbio.2019.07.002. [Epub ahead of print]

PMID:
31284096
2.

Glaucoma Management in Patients with Aniridia and Boston Type 1 Keratoprosthesis.

Nascimento E Silva R, Shen LQ, Chiou CA, Shanbhag SS, Paschalis EI, Pasquale LR, Colby KA, Dohlman CH, Chodosh J, Alves MR.

Am J Ophthalmol. 2019 Jun 24. pii: S0002-9394(19)30294-6. doi: 10.1016/j.ajo.2019.06.018. [Epub ahead of print]

PMID:
31247168
3.

Three-Dimensional Optical Coherence Tomography Imaging for Glaucoma Associated with Boston Keratoprosthesis Type I and II.

Khoueir Z, Jassim F, Braaf B, Poon LY, Tsikata E, Chodosh J, Dohlman CH, Vakoc BJ, Bouma BE, de Boer JF, Chen TC.

J Glaucoma. 2019 Jun 4. doi: 10.1097/IJG.0000000000001280. [Epub ahead of print]

PMID:
31169563
4.

Finding an Optimal Corneal Xenograft Using Comparative Analysis of Corneal Matrix Proteins Across Species.

Sharifi R, Yang Y, Adibnia Y, Dohlman CH, Chodosh J, Gonzalez-Andrades M.

Sci Rep. 2019 Feb 12;9(1):1876. doi: 10.1038/s41598-018-38342-4.

5.

Blood Levels of Tumor Necrosis Factor Alpha and Its Type 2 Receptor Are Elevated in Patients with Boston Type I Keratoprosthesis.

Paschalis EI, Taniguchi EV, Chodosh J, Pasquale LR, Colby K, Dohlman CH, Shen LQ.

Curr Eye Res. 2019 Jun;44(6):599-606. doi: 10.1080/02713683.2019.1568500. Epub 2019 Feb 4.

PMID:
30632412
6.

Microglia Regulate Neuroglia Remodeling in Various Ocular and Retinal Injuries.

Paschalis EI, Lei F, Zhou C, Chen XN, Kapoulea V, Hui PC, Dana R, Chodosh J, Vavvas DG, Dohlman CH.

J Immunol. 2019 Jan 15;202(2):539-549. doi: 10.4049/jimmunol.1800982. Epub 2018 Dec 12.

PMID:
30541880
7.

Permanent neuroglial remodeling of the retina following infiltration of CSF1R inhibition-resistant peripheral monocytes.

Paschalis EI, Lei F, Zhou C, Kapoulea V, Dana R, Chodosh J, Vavvas DG, Dohlman CH.

Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):E11359-E11368. doi: 10.1073/pnas.1807123115. Epub 2018 Nov 15.

8.

The Role of Microglia and Peripheral Monocytes in Retinal Damage after Corneal Chemical Injury.

Paschalis EI, Lei F, Zhou C, Kapoulea V, Thanos A, Dana R, Vavvas DG, Chodosh J, Dohlman CH.

Am J Pathol. 2018 Jul;188(7):1580-1596. doi: 10.1016/j.ajpath.2018.03.005. Epub 2018 Apr 6.

9.

Improving the practicality and safety of artificial corneas: Pre-assembly and gamma-rays sterilization of the Boston Keratoprosthesis.

Gonzalez-Andrades M, Sharifi R, Islam MM, Divoux T, Haist M, Paschalis EI, Gelfand L, Mamodaly S, Di Cecilia L, Cruzat A, Ulm FJ, Chodosh J, Delori F, Dohlman CH.

Ocul Surf. 2018 Jul;16(3):322-330. doi: 10.1016/j.jtos.2018.04.002. Epub 2018 Apr 5.

PMID:
29627599
10.

Colocalization of Galectin-3 With CD147 Is Associated With Increased Gelatinolytic Activity in Ulcerating Human Corneas.

Cruzat A, Gonzalez-Andrades M, Mauris J, AbuSamra DB, Chidambaram P, Kenyon KR, Chodosh J, Dohlman CH, Argüeso P.

Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):223-230. doi: 10.1167/iovs.17-23196.

11.

Chemical Burns of the Eye: The Role of Retinal Injury and New Therapeutic Possibilities.

Dohlman CH, Cade F, Regatieri CV, Zhou C, Lei F, Crnej A, Harissi-Dagher M, Robert MC, Papaliodis GN, Chen D, Aquavella JV, Akpek EK, Aldave AJ, Sippel KC, DʼAmico DJ, Dohlman JG, Fagerholm P, Wang L, Shen LQ, González-Andrades M, Chodosh J, Kenyon KR, Foster CS, Pineda R, Melki S, Colby KA, Ciolino JB, Vavvas DG, Kinoshita S, Dana R, Paschalis EI.

Cornea. 2018 Feb;37(2):248-251. doi: 10.1097/ICO.0000000000001438.

PMID:
29135604
12.

Surface Modifications of the PMMA Optic of a Keratoprosthesis to Improve Biointegration.

Riau AK, Venkatraman SS, Dohlman CH, Mehta JS.

Cornea. 2017 Nov;36 Suppl 1:S15-S25. doi: 10.1097/ICO.0000000000001352. Review.

PMID:
28968294
13.

The Role of the Back Plate in Angle Anatomy with the Boston Type I Keratoprosthesis.

Taniguchi EV, Paschalis EI, Crnej A, Ren A, Colby KA, Chodosh J, Pasquale LR, Shen LQ, Dohlman CH, Cruzat A.

Cornea. 2017 Sep;36(9):1096-1101. doi: 10.1097/ICO.0000000000001248.

PMID:
28614155
14.

Measuring Forward Light Scatter by the Boston Keratoprosthesis in Various Configurations.

Abdelaziz M, Dohlman CH, Sayegh RR.

Cornea. 2017 Jun;36(6):732-735. doi: 10.1097/ICO.0000000000001197.

PMID:
28476052
15.

Mechanisms of Retinal Damage after Ocular Alkali Burns.

Paschalis EI, Zhou C, Lei F, Scott N, Kapoulea V, Robert MC, Vavvas D, Dana R, Chodosh J, Dohlman CH.

Am J Pathol. 2017 Jun;187(6):1327-1342. doi: 10.1016/j.ajpath.2017.02.005. Epub 2017 Apr 13.

16.

Sustained Subconjunctival Delivery of Infliximab Protects the Cornea and Retina Following Alkali Burn to the Eye.

Zhou C, Robert MC, Kapoulea V, Lei F, Stagner AM, Jakobiec FA, Dohlman CH, Paschalis EI.

Invest Ophthalmol Vis Sci. 2017 Jan 1;58(1):96-105. doi: 10.1167/iovs.16-20339.

17.

Endoscopic Cyclophotocoagulation for the Treatment of Glaucoma in Boston Keratoprosthesis Type II Patient.

Poon LY, Chodosh J, Vavvas DG, Dohlman CH, Chen TC.

J Glaucoma. 2017 Apr;26(4):e146-e149. doi: 10.1097/IJG.0000000000000626.

18.

Elevated Neutrophil Elastase in Tears of Ocular Graft-Versus-Host Disease Patients.

Arafat SN, Robert MC, Abud T, Spurr-Michaud S, Amparo F, Dohlman CH, Dana R, Gipson IK.

Am J Ophthalmol. 2017 Apr;176:46-52. doi: 10.1016/j.ajo.2016.12.026. Epub 2017 Jan 8.

PMID:
28073648
19.

Long-term Visual Outcomes and Complications of Boston Keratoprosthesis Type II Implantation.

Lee R, Khoueir Z, Tsikata E, Chodosh J, Dohlman CH, Chen TC.

Ophthalmology. 2017 Jan;124(1):27-35. doi: 10.1016/j.ophtha.2016.07.011. Epub 2016 Aug 15.

PMID:
27538795
20.

Boston keratoprosthesis type I in the elderly.

Homayounfar G, Grassi CM, Al-Moujahed A, Colby KA, Dohlman CH, Chodosh J.

Br J Ophthalmol. 2017 Apr;101(4):514-518. doi: 10.1136/bjophthalmol-2015-307868. Epub 2016 Jul 5.

PMID:
27381593
21.

Tear Matrix Metalloproteinases and Myeloperoxidase Levels in Patients With Boston Keratoprosthesis Type I.

Robert MC, Arafat SN, Spurr-Michaud S, Chodosh J, Dohlman CH, Gipson IK.

Cornea. 2016 Jul;35(7):1008-14. doi: 10.1097/ICO.0000000000000893.

22.

Titanium Coating of the Boston Keratoprosthesis.

Salvador-Culla B, Jeong KJ, Kolovou PE, Chiang HH, Chodosh J, Dohlman CH, Kohane DS.

Transl Vis Sci Technol. 2016 Apr 28;5(2):17. eCollection 2016 Apr.

23.

Effect of Penetrating Keratoplasty and Keratoprosthesis Implantation on the Posterior Segment of the Eye.

Črnej A, Omoto M, Dohlman TH, Gonzalez-Andrades M, Paschalis EI, Cruzat A, Vu TH, Doorenbos M, Chen DF, Dohlman CH, Dana R.

Invest Ophthalmol Vis Sci. 2016 Apr;57(4):1643-8. doi: 10.1167/iovs.15-17557.

24.

Infliximab after Boston Keratoprosthesis in Stevens-Johnson Syndrome: An Update.

Robert MC, Črnej A, Shen LQ, Papaliodis GN, Dana R, Foster CS, Chodosh J, Dohlman CH.

Ocul Immunol Inflamm. 2017 Jun;25(3):413-417. doi: 10.3109/09273948.2016.1145237. Epub 2016 Mar 25.

PMID:
27015032
25.

A Drug Delivery System for Administration of Anti-TNF-α Antibody.

Robert MC, Frenette M, Zhou C, Yan Y, Chodosh J, Jakobiec FA, Stagner AM, Vavvas D, Dohlman CH, Paschalis EI.

Transl Vis Sci Technol. 2016 Mar 11;5(2):11. eCollection 2016 Mar.

26.

Fungal Infections in Boston Keratoprosthesis Patients: Lessons Learned and Novel Developments on the Horizon.

Odorcic S, Sabeti S, Haas W, Durand ML, Dohlman CH.

Semin Ophthalmol. 2016;31(1-2):71-84. doi: 10.3109/08820538.2015.1114871. Review.

PMID:
26959132
27.

Establishment of a novel in vitro model of stratified epithelial wound healing with barrier function.

Gonzalez-Andrades M, Alonso-Pastor L, Mauris J, Cruzat A, Dohlman CH, Argüeso P.

Sci Rep. 2016 Jan 13;6:19395. doi: 10.1038/srep19395.

28.

Fungal Infections After Boston Type 1 Keratoprosthesis Implantation: Literature Review and In Vitro Antifungal Activity of Hypochlorous Acid.

Odorcic S, Haas W, Gilmore MS, Dohlman CH.

Cornea. 2015 Dec;34(12):1599-605. doi: 10.1097/ICO.0000000000000639. Review.

29.

Protective effect of soft contact lenses after Boston keratoprosthesis.

Kammerdiener LL, Speiser JL, Aquavella JV, Harissi-Dagher M, Dohlman CH, Chodosh J, Ciolino JB.

Br J Ophthalmol. 2016 Apr;100(4):549-52. doi: 10.1136/bjophthalmol-2014-306396. Epub 2015 Aug 14.

PMID:
26276169
30.

Periprosthetic Tissue Loss in Patients With Idiopathic Vitreous Inflammation After the Boston Keratoprosthesis.

Grassi CM, Cruzat A, Taniguchi EV, Crnej A, Colby KA, Dohlman CH, Chodosh J.

Cornea. 2015 Nov;34(11):1378-82. doi: 10.1097/ICO.0000000000000557.

PMID:
26226472
31.

Primary implantation of type I Boston keratoprosthesis in nonautoimmune corneal diseases.

Chang HY, Luo ZK, Chodosh J, Dohlman CH, Colby KA.

Cornea. 2015 Mar;34(3):264-70. doi: 10.1097/ICO.0000000000000357.

PMID:
25611395
32.

Stability and in vitro toxicity of an infliximab eye drop formulation.

Robert MC, Spurr-Michaud S, Frenette M, Young D, Gipson IK, Dohlman CH.

Int J Pharm Compd. 2014 Sep-Oct;18(5):418-26.

PMID:
25577892
33.

Retinal detachments after Boston Keratoprosthesis: incidence, predisposing factors, and visual outcomes.

Jardeleza MS, Rheaume MA, Chodosh J, Lane AM, Dohlman CH.

Digit J Ophthalmol. 2015 Dec 21;21(4):1-15. doi: 10.5693/djo.01.2015.10.001. eCollection 2015.

34.

Idiopathic vitritis in the setting of Boston keratoprosthesis.

Grassi CM, Crnej A, Paschalis EI, Colby KA, Dohlman CH, Chodosh J.

Cornea. 2015 Feb;34(2):165-70. doi: 10.1097/ICO.0000000000000328.

PMID:
25526075
35.

Corneal inflammation after miniature keratoprosthesis implantation.

Crnej A, Omoto M, Dohlman TH, Dohlman CH, Dana R.

Invest Ophthalmol Vis Sci. 2014 Dec 16;56(1):185-9. doi: 10.1167/iovs.14-15884.

36.

The Boston keratoprosthesis provides a wide depth of focus.

Sayegh RR, Dohlman CH, Greenstein SH, Peli E.

Ophthalmic Physiol Opt. 2015 Jan;35(1):39-44. doi: 10.1111/opo.12181. Epub 2014 Nov 25.

PMID:
25424372
37.

A review of corneal melting after Boston Keratoprosthesis.

Robert MC, Dohlman CH.

Semin Ophthalmol. 2014 Sep-Nov;29(5-6):349-57. doi: 10.3109/08820538.2014.959186. Review.

PMID:
25325860
38.

UV cross-linking of donor corneas confers resistance to keratolysis.

Arafat SN, Robert MC, Shukla AN, Dohlman CH, Chodosh J, Ciolino JB.

Cornea. 2014 Sep;33(9):955-9. doi: 10.1097/ICO.0000000000000185.

39.

[The Boston keratoprosthesis].

Wang L, Huang Y, James C, Dohlman CH.

Zhonghua Yan Ke Za Zhi. 2014 Apr;50(4):307-12. Chinese.

PMID:
24931158
40.

A novel murine model for keratoprosthesis.

Crnej A, Omoto M, Dohlman TH, Graney JM, Dohlman CH, Drnovsek-Olup B, Dana R.

Invest Ophthalmol Vis Sci. 2014 May 15;55(6):3681-5. doi: 10.1167/iovs.14-14058.

41.

Reliable intraocular pressure measurement using automated radio-wave telemetry.

Paschalis EI, Cade F, Melki S, Pasquale LR, Dohlman CH, Ciolino JB.

Clin Ophthalmol. 2014 Jan 7;8:177-85. doi: 10.2147/OPTH.S54753. eCollection 2014.

42.

Glaucoma progression and role of glaucoma surgery in patients with Boston keratoprosthesis.

Crnej A, Paschalis EI, Salvador-Culla B, Tauber A, Drnovsek-Olup B, Shen LQ, Dohlman CH.

Cornea. 2014 Apr;33(4):349-54. doi: 10.1097/ICO.0000000000000067.

PMID:
24531120
43.

Alkali burn to the eye: protection using TNF-α inhibition.

Cade F, Paschalis EI, Regatieri CV, Vavvas DG, Dana R, Dohlman CH.

Cornea. 2014 Apr;33(4):382-9. doi: 10.1097/ICO.0000000000000071.

PMID:
24488127
44.

Infectious endophthalmitis in Boston keratoprosthesis: incidence and prevention.

Behlau I, Martin KV, Martin JN, Naumova EN, Cadorette JJ, Sforza JT, Pineda R 2nd, Dohlman CH.

Acta Ophthalmol. 2014 Nov;92(7):e546-55. doi: 10.1111/aos.12309. Epub 2014 Jan 25.

45.

Low-cost and readily available tissue carriers for the Boston keratoprosthesis: a review of possibilities.

Cruzat A, Tauber A, Shukla A, Paschalis EI, Pineda R, Dohlman CH.

J Ophthalmol. 2013;2013:686587. doi: 10.1155/2013/686587. Epub 2013 Nov 24. Review.

46.

Very low risk of light-induced retinal damage during Boston keratoprosthesis surgery: a rabbit study.

Salvador-Culla B, Behlau I, Sayegh RR, Stacy RC, Dohlman CH, Delori F.

Cornea. 2014 Feb;33(2):184-90. doi: 10.1097/ICO.0000000000000029.

PMID:
24322800
47.

Wound anatomy after type 1 Boston KPro using oversized back plates.

Cruzat A, Shukla A, Dohlman CH, Colby K.

Cornea. 2013 Dec;32(12):1531-6. doi: 10.1097/ICO.0b013e3182a854ac.

PMID:
24097186
48.

Neutrophil collagenase, gelatinase, and myeloperoxidase in tears of patients with stevens-johnson syndrome and ocular cicatricial pemphigoid.

Arafat SN, Suelves AM, Spurr-Michaud S, Chodosh J, Foster CS, Dohlman CH, Gipson IK.

Ophthalmology. 2014 Jan;121(1):79-87. doi: 10.1016/j.ophtha.2013.06.049. Epub 2013 Aug 17.

49.

In vitro and in vivo assessment of titanium surface modification for coloring the backplate of the Boston keratoprosthesis.

Paschalis EI, Chodosh J, Spurr-Michaud S, Cruzat A, Tauber A, Behlau I, Gipson I, Dohlman CH.

Invest Ophthalmol Vis Sci. 2013 Jun 4;54(6):3863-73. doi: 10.1167/iovs.13-11714.

PMID:
23661373
50.

The Boston keratoprosthesis type I in mucous membrane pemphigoid.

Palioura S, Kim B, Dohlman CH, Chodosh J.

Cornea. 2013 Jul;32(7):956-61. doi: 10.1097/ICO.0b013e318286fd73.

PMID:
23538625

Supplemental Content

Loading ...
Support Center